The Society for Immunotherapy of Cancer's (SITC) Toxicity Management Working Group reports that targeted therapy of PD-1/PDL-1 and CTLA-4 is associated with pneumonitis in less than 5% of cases overall, with severe complications (grade three or higher) occurring in only 1-2% of patients 138. Here, PDCD1 is linked to pneumonitis.